Anti-PD-1-associated organizing pneumonia in a responding melanoma patient.
Department of Laboratory Medicine and Pathobiology.
P O
PO
Fiset
Department of Medicine, Division of Respirology.
S
S
Shapera
Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada.
M O
MO
Butler
Department of Laboratory Medicine and Pathobiology Department of Medical Oncology, Princess Margaret Hospital, University Health Network, Toronto, ON, Canada ming.tsao@uhn.on.ca.
M-S
MS
Tsao
D061067:Antibodies, Monoclonal, Humanized / Q000009:adverse effects*; D000074322:Antineoplastic Agents, Immunological / Q000009:adverse effects*; D006801:Humans; D008297:Male; D008545:Melanoma / Q000175:diagnosis / Q000188:drug therapy*; D008875:Middle Aged; D011014:Pneumonia / Q000139:chemically induced* / Q000175:diagnosis; D061026:Programmed Cell Death 1 Receptor / Q000037:antagonists & inhibitors*; D012878:Skin Neoplasms / Q000175:diagnosis / Q000188:drug therapy*
D061067:Antibodies, Monoclonal, Humanized; D000074322:Antineoplastic Agents, Immunological; C105992:PDCD1 protein, human; D061026:Programmed Cell Death 1 Receptor; C582435:pembrolizumab